期刊论文Comparative Efficacy of China's Domestic versus Imported PD-1/PD-L1 Inhibitor-Based Combinations as First-Line Therapy for Advanced Non-small Cell Lung …复制

DOI:复制

文献链接:复制

其他信息:

J Yang, R Min, H Zhong, Y Hu
Available at SSRN 6021360
papers.ssrn.com
Background: Advanced non-small cell lung cancer (NSCLC) imposes a heavy global burden, with the need for optimal first-line programmed cell death protein 1 (PD-1)/cell death protein ligand 1 (PD-L1) inhibitor combination therapies remaining unmet. This study aimed to comprehensively compare the efficacy of approved PD-1/PD-L1 inhibitor combinations, including agents developed in China, to provide evidence-based treatment recommendations. Methods: This systematic review and network meta-analysis followed the …